Insider Selling: Replimune Group (NASDAQ:REPL) CFO Sells 9,154 Shares of Stock

Key Points

• Replimune Group CFO Emily Luisa Hill sold 9,154 shares of stock at an average price of $5.37, decreasing her ownership by 6.38% and leaving her with 134,368 shares valued at approximately $721,556.16.
• The company's most recent earnings report showed a loss of ($0.95) EPS, missing consensus estimates by ($0.12), with analysts projected to forecast a total of ($2.97) EPS for the fiscal year.
• Research analysts have downgraded Replimune Group's ratings significantly, with the average target price lowered to $7.67 and a majority rating of "Hold" from various investment firms.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) CFO Emily Luisa Hill sold 9,154 shares of Replimune Group stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $5.37, for a total value of $49,156.98. Following the transaction, the chief financial officer directly owned 134,368 shares in the company, valued at $721,556.16. The trade was a 6.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Replimune Group Trading Down 0.9%

REPL traded down $0.05 during midday trading on Tuesday, hitting $5.28. 1,860,383 shares of the company were exchanged, compared to its average volume of 24,347,400. The firm has a market capitalization of $412.16 million, a P/E ratio of -1.63 and a beta of 0.67. Replimune Group, Inc. has a 1-year low of $2.68 and a 1-year high of $17.00. The firm's 50 day moving average price is $8.04 and its 200-day moving average price is $9.46. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). As a group, equities analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

REPL has been the subject of several research analyst reports. Jefferies Financial Group lowered their price objective on Replimune Group from $31.00 to $6.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. HC Wainwright lowered Replimune Group from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 23rd. Barclays lowered Replimune Group from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $17.00 to $3.00 in a research report on Wednesday, July 23rd. Leerink Partnrs lowered Replimune Group from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 22nd. Finally, Piper Sandler lowered Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 price objective for the company. in a research report on Tuesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $7.67.

Institutional Trading of Replimune Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC increased its position in Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after buying an additional 1,655 shares in the last quarter. US Bancorp DE increased its position in Replimune Group by 582.6% in the 1st quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after buying an additional 3,921 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after purchasing an additional 5,922 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock valued at $64,000 after purchasing an additional 1,879 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Replimune Group during the 2nd quarter valued at about $69,000. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.